Most cited papers from Amyloidosis Foundation
What are the most cited papers from Amyloidosis Foundation?
The most cited paper from Amyloidosis Foundation is "Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis" (David H Adams et al., 2018), with 3,046 citations. Next come "Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy" (2,841) and "CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis" (1,751).
Showing 50 of 60 papers. Every paper with more than 169 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis David H Adams et al. · New England Journal of Medicine | 4 Jul 2018 | 3,046 |
| 2 | Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy Matthew J. Maurer et al. · New England Journal of Medicine | 27 Aug 2018 | 2,841 |
| 3 | CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis Julian David Gillmore et al. · New England Journal of Medicine | 26 Jun 2021 | 1,751 |
| 4 | Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia Willemijn J. Jansen et al. · JAMA | 19 May 2015 | 1,662 |
| 5 | Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis Merrill Douglas Benson et al. · New England Journal of Medicine | 4 Jul 2018 | 1,454 |
| 6 | Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis Morie Abraham Gertz, Ray Comenzo, Rodney H. Falk et al. · American Journal of Hematology | 2005 | 1,438 |
| 7 | Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases Pablo García‐Pavía et al. · European Heart Journal | 2 Feb 2021 | 1,221 |
| 8 | The Systemic Amyloidoses Rodney H. Falk, Raymond L. Comenzo, Martha Skinner · New England Journal of Medicine | 25 Sep 1997 | 1,194 |
| 9 | Systemic amyloidosis Ashutosh D. Wechalekar, Julian David Gillmore, Philip Nigel Hawkins · The Lancet | 21 Dec 2015 | 1,006 |
| 10 | Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis Teresa Coelho et al. · New England Journal of Medicine | 28 Aug 2013 | 981 |
| 11 | Natural History and Outcome in Systemic AA Amyloidosis Helen J. Lachmann, Hugh J.B. Goodman, Janet A. Gilbertson et al. · New England Journal of Medicine | 6 Jun 2007 | 899 |
| 12 | Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society Alexander Richard Lyon et al. · European Journal of Heart Failure | 28 May 2020 | 823 |
| 13 | Natural history and outcome in systemic AA amyloidosis Lachmann, HJ, Goodman, HJB, Gilbertson, JA et al. · UCL Discovery (University College London) | 7 Jun 2007 | 782 |
| 14 | Repurposing Diflunisal for Familial Amyloid Polyneuropathy John L. Berk et al. · JAMA | 25 Dec 2013 | 711 |
| 15 | Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis Efstathios Kastritis et al. · New England Journal of Medicine | 30 Jun 2021 | 703 |
| 16 | Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis Helen Jane Lachmann, David Richmond Booth, Susanne E. Booth et al. · New England Journal of Medicine | 6 Jun 2002 | 689 |
| 17 | Classification criteria for autoinflammatory recurrent fevers Marco Gattorno et al. · Annals of the Rheumatic Diseases | 24 Apr 2019 | 593 |
| 18 | Systemic immunoglobulin light chain amyloidosis Giampaolo Merlini, Angela Dispenzieri, Vaishali Sanchorawala et al. · Nature Reviews Disease Primers | 25 Oct 2018 | 572 |
| 19 | Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis Mathew S. Maurer, Sabahat Bokhari, Thibaud Damy et al. · Circulation Heart Failure | Sep 2019 | 563 |
| 20 | Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy Julian David Gillmore et al. · New England Journal of Medicine | 10 Jan 2024 | 532 |
| 21 | T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 + T cells Giuseppina Arbore et al. · Science | 16 Jun 2016 | 524 |
| 22 | Systemic exosomal siRNA delivery reduced alpha‐synuclein aggregates in brains of transgenic mice Jonathan M. Cooper, Oscar P. B. Wiklander, Joel Z. Nordin et al. · Movement Disorders | 11 Aug 2014 | 515 |
| 23 | Amyloidosis: Pathogenesis and New Therapeutic Options Giampaolo Merlini, David C. Seldin, Morie Abraham Gertz · Journal of Clinical Oncology | 12 Apr 2011 | 513 |
| 24 | Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes Fabrizio De Benedetti et al. · New England Journal of Medicine | 16 May 2018 | 489 |
| 25 | Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis Morie Abraham Gertz, Merrill Douglas Benson, P. James B. Dyck et al. · Journal of the American College of Cardiology | 23 Nov 2015 | 485 |
| 26 | Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis Scott David Solomon, David H Adams, Arnt V. Kristen et al. · Circulation | 17 Jan 2019 | 465 |
| 27 | Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy Helen Jane Lachmann, Ruth Gallimore, Julian David Gillmore et al. · British Journal of Haematology | 20 Jun 2003 | 436 |
| 28 | Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging Adam Castaño, Muhammad Haq, David L. Narotsky et al. · JAMA Cardiology | 24 Aug 2016 | 424 |
| 29 | Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial David H Adams, Ivailo Tournev, Mark Taylor et al. · Amyloid | 23 Jul 2022 | 401 |
| 30 | Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component Duncan Richards, Louise M. Cookson, Aliénor Berges et al. · New England Journal of Medicine | 15 Jul 2015 | 382 |
| 31 | Senile Systemic Amyloidosis Presenting With Heart Failure Belinda Ng, Lawreen Heller Connors, Ravin Davidoff et al. · Archives of Internal Medicine | 27 Jun 2005 | 370 |
| 32 | Diagnosis and Treatment of Cardiac Amyloidosis. A Position Statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Pablo García‐Pavía et al. · European Journal of Heart Failure | Apr 2021 | 344 |
| 33 | The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry Helen Jane Lachmann et al. · Annals of the Rheumatic Diseases | 22 Aug 2013 | 341 |
| 34 | Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis Mathew S. Maurer et al. · New England Journal of Medicine | 25 Oct 2023 | 335 |
| 35 | Rapid Proton-Detected NMR Assignment for Proteins with Fast Magic Angle Spinning Emeline Barbet‐Massin et al. · Journal of the American Chemical Society | 7 Aug 2014 | 326 |
| 36 | Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy David H Adams, Yukio Ando, João Melo Beirão et al. · Journal of Neurology | 6 Jan 2020 | 324 |
| 37 | Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis Efstathios Kastritis, Ashutosh D. Wechalekar, Meletios Athanasios Dimopoulos et al. · Journal of Clinical Oncology | 20 Jan 2010 | 301 |
| 38 | Aortic Stenosis and Cardiac Amyloidosis Julien Ternacle, Laura Krapf, Dania Mohty et al. · Journal of the American College of Cardiology | Nov 2019 | 297 |
| 39 | Systemic Amyloidosis in E ngland: an epidemiological study Jennifer Helen Pinney, Colette J Smith, Jessi B. Taube et al. · British Journal of Haematology | 11 Mar 2013 | 290 |
| 40 | Intracardiac Thrombosis and Anticoagulation Therapy in Cardiac Amyloidosis DaLi Feng, Imran S. Syed, Matthew W. Martinez et al. · Circulation | 4 May 2009 | 286 |
| 41 | Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine Giovanni O. Palladini, Paola Rosalba Russo, Tiziana Bosoni et al. · Clinical Chemistry | 8 Jan 2009 | 281 |
| 42 | Recommendations for the management of autoinflammatory diseases Nienke M. ter Haar et al. · Annals of the Rheumatic Diseases | 25 Jun 2015 | 278 |
| 43 | Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium Isabelle Lousada, Raymond L. Comenzo, Heather Jolie Landau et al. · Advances in Therapy | Oct 2015 | 277 |
| 44 | Eprodisate for the Treatment of Renal Disease in AA Amyloidosis Laura M. Dember, Philip Nigel Hawkins, Bouke P. C. Hazenberg et al. · New England Journal of Medicine | 6 Jun 2007 | 274 |
| 45 | Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis Michele Boldrini et al. · JACC. Cardiovascular imaging | 18 Dec 2019 | 270 |
| 46 | Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers Silvia Federici et al. · Annals of the Rheumatic Diseases | 31 Jan 2015 | 270 |
| 47 | Epidemiology of Cardiac Amyloidosis–Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States Lauren Gray Gilstrap, Francesca Dominici, Yun Wang et al. · Circulation Heart Failure | Jun 2019 | 262 |
| 48 | Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis Mazen A Hanna, Frederick L. Ruberg, Matthew J. Maurer et al. · Journal of the American College of Cardiology | Jun 2020 | 254 |
| 49 | Evolving landscape in the management of transthyretin amyloidosis Philip Nigel Hawkins, Yukio Ando, Angela Dispenzeri et al. · Annals of Medicine | 17 Nov 2015 | 248 |
| 50 | Cardiac Amyloidosis Due to Transthyretin Protein Frederick L. Ruberg, Matthew J. Maurer · JAMA | 5 Mar 2024 | 245 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.